Business Wire

  1. Wheeler Financial From Pitney Bowes Helps Thoroughbred Diagnostic Labs Secure Funding For New Laboratory Screening Technology

    Pitney Bowes Inc., a global technology company that provides commerce solutions in the areas of ecommerce, shipping, mailing, data and financial services, today announced that Wheeler Financial from Pitney Bowes has closed a financing transaction with Thoroughbred Diagnostic Labs

  2. US Medical Innovations Receives FDA 510(k) Clearance For The Canady Plasma Smart XL-1000 Generator

    US Medical Innovations, LLC (USMI), a Biomedical and Life Science subsidiary of US Patent Innovations, LLC (USPI) announced today the U.S. Food And Drug Administration (FDA) 510(k) clearance (#K192124) to market and sell the Canady Plasma Smart XL-1000 Electrosurgical Generator (CPSXEG) with accessories

  3. PharmaCyte Biotech 'Release Testing' Successful On All Completed Tests Of Clinical Trial Product

    PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today an update on the completed tests that are part of the U.S. Food and Drug Administration (FDA) required “release testing” related to the company's first manufactured batch of its clinical trial product to be used in its planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer

  4. Alliance Laboratories Now Providing Hundreds Of Blood & Pathology Tests In Seven States

    Alliance Laboratories, an independent full-service laboratory founded in June of 2000, has announced the milestone of delivering over 20 million test results to patients and physicians in seven states: California, Connecticut, Florida, New Jersey, New York, Pennsylvania and Illinois

  5. Castle Biosciences Presents Expanded Data Supporting Use Of DecisionDx-Melanoma Test To Inform Sentinel Lymph Node Biopsy Recommendations

    Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data from an expanded, multi-center, prospectively tested patient cohort study supporting clinical use of the DecisionDx-Melanoma test to inform discussions and recommendations regarding sentinel lymph node biopsy (SLNB), as well as data from a separate multi-center prospective outcomes study

  6. Zoetis Acquires ZNLabs, A Nationwide Veterinary Reference Laboratory, To Further Strengthen Its Comprehensive Diagnostics Portfolio

    Zoetis Inc. today announced the acquisition of ZNLabs, a full-service veterinary clinical reference laboratory company with a network of labs across the U.S

  7. Agilent Announces Applications Open For LabCentral Golden Ticket

    Agilent Technologies Inc. has announced that the nomination process to submit proposals to receive an Agilent-sponsored LabCentral Golden Ticket is open for interested life sciences and biotech startup companies

  8. College Of American Pathologists And Seoul National University Host Advanced Education For Doctors And Laboratory Scientists

    In an effort to foster laboratory quality and further advance the evolving field of clinical microbiology, the College of American Pathologists (CAP), in partnership with Seoul National University College of Medicine (SNUCM), will host a daylong educational course for approximately 150 pathologists and laboratory professionals at Seoul National University Hospital (SNUH) Nov. 18

  9. Canon Medical Supports Expert Forums On Advancements In Imaging Technology At RSNA 2019

    In an effort to help clinicians stay current with the latest advancements in medical imaging, Canon Medical Systems, USA, through an unrestricted educational grant, invites you to expert-led forums at this year’s Radiological Society of North America (RSNA) annual meeting, December 1-7, 2019 in Chicago, IL

  10. FDA Grants De Novo Designation For Vela Diagnostics’ Next Generation Sequencing HIV-1 Genotyping Assay

    Vela Diagnostics announced recently that it has received FDA authorization to market its in vitro diagnostic test for the detection of HIV-1 genomic drug resistance mutations (DRMs)